Drug therapy: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection

New England Journal of Medicine

Volumn 342, Issue 19, 2000, Pages 1416-1429

  Kovacs, Joseph A ^a   Masur, Henry ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ASTEMIZOLE; ATOVAQUONE; AZITHROMYCIN; CIDOFOVIR; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FAMCICLOVIR; FLUCONAZOLE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; ISONIAZID; ITRACONAZOLE; NEVIRAPINE; PENTAMIDINE; PYRAZINAMIDE; PYRIDOXINE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SULFADIAZINE; UNINDEXED DRUG; VALACICLOVIR; TUBERCULOSTATIC AGENT;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; INFECTION SENSITIVITY; LUNG TUBERCULOSIS; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TOXOPLASMOSIS; AIDS RELATED COMPLEX; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; DRUG INTERACTION; IMMUNOLOGY; PRACTICE GUIDELINE; RECURRENT DISEASE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CHEMOPREVENTION; DRUG INTERACTIONS; GANCICLOVIR; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; RECURRENCE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0034636302     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200005113421907     Document Type: Review

References (112)

1. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.
2. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-31.
3. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981;305:1431-8.
4. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981;305:1439-44.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
6. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 1999;48(SS-2):1-22.
7. Miller V, Staszewski S, Nisius G, Lepri AC, Sabin C, Phillips AN. Risk of new AIDS diseases in people on triple therapy. Lancet 1999;353:463-4.
8. Ledergerber B, Egger M, Opravil MR, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. Lancet 1999;353: 863-8.
9. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Rep 1999;48(RR-10):1-66.
10. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):4-19.
11. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:113. abstract.
12. Costagliola D. Clinical manifestations of HIV infections in the era of highly active antiretroviral treatment (HAART) in France. In: Abstracts of the 12th International Conference on AIDS, Geneva, June 28-July 3, 1998:82. abstract.
13. Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999;21: Suppl 1:S27-S30.
14. Lundgren JD, Johnson A, Pradier C, et al. The changing spectrum of AIDS across Europe: 1994-1999: the EuroSIDA study. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999. Washington, D.C.: American Society for Microbiology, 1999:91. abstract.
15. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(RR-12):1-46.
16. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989;38:Suppl 5:1-9.
17. Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904.
18. Giorgi J, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998;12:1833-44.
19. Engels EA, Rosenberg PS, O'Brien TR, Goedert JJ. Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: a measure of current immune suppression: Multicenter Hemophilia Cohort Study. Ann Intern Med 1999;131:256-64.
20. Kaplan JE, Hanson DL, Dworkin MS, Jones JL. HIV plasma RNA, an independent predictor of opportunistic infections in HIV-infected persons. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999. Washington, DC.: American Society for Microbiology, 1999:13. abstract.
21. Immunological markers in HIV-infected pregnant women. AIDS 1997;11:1859-65.
22. 1995 Revised guidelines for prophylaxis against Pneumocystic carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1995;44(RR-4):1-11.
23. Zurlo JJ, Wood L, Gaglione MM, Polis MA. Effect of splenectomy on T lymphocyte subsets in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:768-71.
24. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
25. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999;130:570-7.
26. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998;47(RR-20):1-58.
27. Richards FO Jr, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:Suppl 1:S49-S56.
28. Stewart JA, Reef SE, Pellett PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21.Suppl 1:S114-S120.
29. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 1997;35:2745-7.
30. Tsolaki AG, Miller RF, Underwood AP, Banerji S, Wakefield AE. Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J Infect Dis 1996;174:141-56.
31. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21:Suppl 1:S32-S43.
32. Ward JW, Hanson DL, Jones J, Kaplan J. Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons. In: Program and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, September 18-20, 1996:81. abstract.
33. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
34. Nielsen H, Kvinesdal B, Benfield T, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30:597-601.
35. Fleming C, Cilento J, Steger K, McNamara E, Pelton S, Craven D. Immunogenicity of revaccination with pneumococcal vaccine in HIV-infected patients on combination antiretroviral therapy. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:123. abstract.
36. Vento S, Garofano T, Rcnzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
37. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:430-3.
38. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. Clin Infect Dis 1995;21:106-13.
39. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998;178:1126-32.
40. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
41. Schneider MME, Hoepelman AIM, Eeeftinck Schattenkerk JKM, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
42. Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis 1995;171:1632-6.
43. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med 1992;327:1842-8.
44. El-Sadr W, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons: Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 1999;29:775-83.
45. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11.
46. Para MF, Dohn M, Frame P, et al. ACTG 268 Trial - gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP). In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997:65. abstract.
47. Leoung G, Stanford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct rechallenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever. In: Addendum to Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997. abstract.
48. Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
49. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531-41.
50. Girard P-M, Landman R, Gaudebout C, et al Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection N Engl J Med 1993;328:1514-20.
51. Pearson RD, Hewlett EL. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med 1985; 103:782-6.
52. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998;339:1889-95.
53. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroatc synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999;180:1969-78.
54. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999;354:1347-51.
55. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa prophylaxis and with sulfa treatment failure in AIDS patients. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:119. abstract.
56. Halsey NA, Coberly JS, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-92.
57. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8.
58. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12: 2447-57.
59. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997;11:875-82.
60. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-20.
61. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial: Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 2000;283:1445-50.
62. Graham NMH, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156:889-94.
63. The USPHS Rifapentine Trial Group, Vemon A, Khan A, Bozeman L, Wang YC. Update on US Public Health Service (USPHS) Study 22: a trial of once weekly isoniazid (INH) & rifapentine (RPT) in the continuation phase of TB treatment. Am J Respir Crit Care Med 1998;157:Suppl: A467. abstract.
64. Flexner C, Piscitelli SC. Drug administration and interactions. In: Dolin R, Masur H, Saag MS, eds. AIDS therapy. New York: Churchill Livingstone, 1999:785-97.
65. Benson CA, Cohn DL, Williams P, ACTG 196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA+RBT for prevention of Mycobacterium avium complex (MAC) disease in HIV+ patients with CD4 counts ≤100 cells/μL. In: Proceedings of the Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996:91. abstract.
66. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
67. Havlir DV, Dubé MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
68. Dunne MW, Bozzette S, McCutchan JA, et al. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomized trial. Lancet 1999;354:891-5.
69. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
70. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals: Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998;12: 269-77.
71. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
72. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1997;126: 689-96.
73. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998;27:1369-75.
74. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999;28:1049-56.
75. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999;28:1080-5.
76. Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin Infect Dis 1999;29:125-33.
77. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
78. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999;340:1063-70.
79. Studies of the Ocular Complications of AIDS (SOCA), AIDS Clinical Trials Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J Infect Dis 1997;176:50-8.
80. Martin D, Sierra-Madero J, Walmsley S, Wolitz R, Brown F, Robinson C. Valganciclovir (VGCV) vs. IV ganciclovir (GCV) as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis: a randomized, controlled study. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:119. abstract.
81. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
82. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial: a randomized, controlled trial. Ann Intern Med 1997;126:264-74.
83. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
84. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:580-4.
85. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
86. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:291-6.
87. Podzamczer D, Miro JM, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1995;123:175-80.
88. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992;116:33-43.
89. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996;22:268-75.
90. Wheat J. Histoplasmosis. In: Dolin R, Masur H, Saag MS, eds. AIDS therapy. New York: Churchill Livingstone, 1999:412-22.
91. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6.
92. Ampel NM. Coccidioidomycosis. In: Dolin R, Masur H, Saag MS, eds. AIDS therapy. New York: Churchill Livingstone, 1999;423-32.
93. Schneider MME, Borleffs JCC, Stolk RP, Jaspers CA, Hoepelman AI. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3.
94. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999;340: 1301-6.
95. Lopez JC, Miro JM, Pena JM, Podzamczer D. Discontinuation of PCP prophylaxis is safe in HIV-infected patients after immunological recovery with HAART: results of the Gesida 04/98 study. In: Addendum to Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999. Washington, D.C.: American Society for Microbiology, 1999:19. abstract.
96. Dworkin M, Hanson D, Jones J, Kaplan J, Adult/Adolescent Spectrum of HIV Disease Project (ASD). The risk for Pneumocystis carinii pneumonia (PCP) and disseminated nontuberculous mycobactcriosis (dMb) after an antiretroviral therapy (ART) associated increase in the CD4+ T-lymphocyte count. In: Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999:198. abstract.
97. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999;13:1647-51.
98. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999;353:1293-8.
99. Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in padents with HIV infection. Ann Intern Med 2000;132:201-5.
100. Currier JS, Williams PL, Koletar S, et al. A randomized, placebo-controlled trial of azithromycin prophylaxis for the prevention of mycobacterium avium complex (MAC) in subjects with increases in CD4 cells on antiretroviral therapy. In: Addendum to Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999. Washington, D.C.: American Society for Microbiology, 1999:19. abstract.
101. Furrer H, Talenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis against M. avium in patients on successful antiretroviral combination therapy: the Swiss HIV Cohort experience. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:122. abstract.
102. 3 who responded to antiretroviral therapy: results of a placebo-controlled trial (CPCRA 048). In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:122. abstract.
103. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anti-cytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis. JAMA 1999;282:1633-7
104. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
105. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-3.
106. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998;105:1259-64.
107. Furrer H, Opravil M, Rossi M, et al. The Swiss StopCox Study: is it safe to discontinue PCP prophylaxis in patients with detectable viremia, low nadir CD4 count or T. gondii seropositivity? In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:122. abstract.
108. Miro JM, Lopez JC, Podzamczer D, et al. Discontinuation of toxoplasmic encephalitis prophylaxis is safe in HIV-1 and T. gondii co-infected patients after immunological recovery with HAART: preliminary results of the GESIDA 04/98-B Study. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:119. abstract.
109. Ledergerber B, Mocroft A, Reiss P, et al. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: results from eight prospective European cohorts. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:235. abstract.
110. Koletar SL, Heald AE, Murphy RL, et al. Discontinuing primary and secondary PCP prophylaxis in patients who have increased CD4 counts in response to antiretroviral therapy: preliminary results - ACTG 888. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:122. abstract.
111. Aberg JA, Price RW, Heeren DM, Pearce RB, Bredt B. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:123. abstract.
112. Johnson S, Benson C, Johnson D, Weinberg A. Recurrent cytomegalovirus (CMV) retinitis in a patient on highly active antiretroviral therapy (HAART) despite apparent immune reconstitution. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:127. abstract.